Fig. 4From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final resultsProgression-free survival (a) and overall survival (b), intent-to-treat population (Cohort 1). Median overall survival was not reached. The tick marks indicate censoring eventsBack to article page